Key Highlights
- Samuel Bakhoum, co-founder, named Chief Scientific Officer at Volastra Therapeutics.
- Dr. Bakhoum joins from Memorial Sloan Kettering, known for expertise in chromosomal instability.
- His appointment strengthens Volastra’s clinical leadership and innovative cancer therapies.
Source: Business Wire
Notable Quotes
- “We are incredibly excited to welcome Sam to the Volastra team at such a pivotal moment in the company’s growth.” — Charles Hugh-Jones, M.D., FRCP, Chief Executive Officer at Volastra
- “I am thrilled to join Volastra’s leadership as it advances the field in discovering therapies targeting chromosomal instability.” — Samuel Bakhoum, M.D., Ph.D., Chief Scientific Officer at Volastra
- “His scientific acumen and innovative thinking around cancer research will add greatly to our capabilities.” — Sandi Peterson, Chair of the Board at Volastra
SoHC's Take
The appointment of Samuel Bakhoum as Volastra’s CSO marks a strategic step forward for the company as it continues to innovate in the cancer treatment landscape. Bakhoum’s expertise in chromosomal instability, a key driver of cancer progression, aligns perfectly with Volastra’s mission of targeting this fundamental mechanism. His leadership will likely accelerate the clinical development of their KIF18A inhibitors and bolster their pipeline of discovery-stage therapies. This move positions Volastra as a pioneering force in oncology, potentially transforming how cancers are treated in the future.
